Skip to content
Peptidepedia

Tirzepatide Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

Tirzepatide is administered via subcutaneous injection once weekly. The standard initiation and titration schedule is designed to minimize gastrointestinal side effects during dose escalation:

  • Weeks 1–4: 2.5 mg weekly
  • Weeks 5–8: 5 mg weekly
  • Weeks 9–12: 7.5 mg weekly
  • Weeks 13–16: 10 mg weekly
  • Weeks 17–20: 12.5 mg weekly
  • Week 21+: 15 mg weekly (maximum)

Not all individuals require escalation to the maximum 15 mg dose. Many achieve satisfactory glycemic control or weight loss targets at 5 mg or 10 mg with a more favorable side effect profile. Extending titration intervals to 6–8 weeks per step (rather than the standard 4 weeks) is recommended for most patients, as slower titration substantially reduces GI side effects and treatment discontinuation without compromising long-term efficacy.

The minimum interval between doses is 72 hours, providing some flexibility when a consistent weekly day is not achievable.

Frequently Asked Questions

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide targets only GLP-1 receptors. Head-to-head trials (SURPASS-2) show tirzepatide produces greater weight loss and HbA1c reduction at all doses compared to semaglutide 1 mg weekly.

If fewer than 4 days (96 hours) have passed since the missed dose, administer it immediately. If more than 4 days have passed, skip the missed dose and resume your regular weekly schedule. Do not double dose.

Eating smaller, more frequent meals, avoiding high-fat foods, staying well hydrated, and eating slowly all help reduce nausea. If symptoms are severe, extending the titration schedule or temporarily reducing the dose may provide relief. Most nausea improves as the body adjusts.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
  3. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
  4. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155.
  5. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness. Cardiovasc Diabetol. 2022;21(1):66.
  6. Samms RJ, et al. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421.
  7. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. November 2023.
  8. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. 2022.
  9. World Anti-Doping Agency. The Prohibited List 2024.
  10. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
←Read the full Tirzepatide guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”